Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases.
Breast cancer
HER2 conversion
HER2 targeted therapy
HER2-low
Trastuzumab
Trastuzumab deruxtecan
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
09
09
2022
accepted:
14
11
2022
medline:
19
7
2023
pubmed:
1
12
2022
entrez:
30
11
2022
Statut:
ppublish
Résumé
Therapeutic options for breast cancer (BC) treatment are constantly evolving. The Human Epidermal Growth Factor 2 (HER2)-low BC entity is a new subgroup, representing about 55% of all BC patients. New antibody-drug conjugates demonstrated promising results for this BC subgroup. Currently, there is limited information about the conversion of HER2 subtypes between primary tumor and recurrent disease. This retrospective study included women with BC at the University Medical Centre Wuerzburg from 1998 to 2021. Data were retrieved from patients' records. HER2 evolution from primary diagnosis to the first relapse and the development of secondary metastases was investigated. In the HR-positive subgroup without HER2 overexpression, HER2-low expression in primary BC was 56.7 vs. 14.6% in the triple-negative subgroup (p < 0.000). In the cohort of the first relapse, HER2-low represented 64.1% of HR-positive vs. 48.2% of the triple-negative cohort (p = 0.03). In patients with secondary metastases, HER2-low was 75.6% vs. 50% in the triple negative subgroup (p = 0.10). The subgroup of HER2-positive breast cancer patients numerically increased in the course of disease; the HER2-negative overall cohort decreased. A loss of HER2 expression from primary BC to the first relapse correlated with a better OS (p = 0.018). No clinicopathological or therapeutic features could be identified as potential risk factors for HER2 conversion. HER2 expression is rising during the progression of BC disease. In view of upcoming therapeutical options, the re-analysis of newly developed metastasis will become increasingly important.
Identifiants
pubmed: 36451043
doi: 10.1007/s00432-022-04486-0
pii: 10.1007/s00432-022-04486-0
pmc: PMC10349762
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5417-5428Informations de copyright
© 2022. The Author(s).
Références
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol 38(12):1346–1366. https://doi.org/10.1200/JCO.19.02309
doi: 10.1200/JCO.19.02309
pubmed: 31928404
Alves FR, Gil L, Vasconcelos de Matos L, Baleiras A, Vasques C, Neves MT, Ferreira A, Fontes-Sousa M, Miranda H, Martins A (2022) Impact of human epidermal growth factor receptor 2 (HER2) low status in response to neoadjuvant chemotherapy in early breast cancer. Cureus 14(2):e22330. https://doi.org/10.7759/cureus.22330
doi: 10.7759/cureus.22330
pubmed: 35371692
pmcid: 8938239
Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 20(8):1124–1135. https://doi.org/10.1016/S1470-2045(19)30328-6
doi: 10.1016/S1470-2045(19)30328-6
pubmed: 31257177
Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies [Review]. Nat Rev Immunol 10(5):345–352. https://doi.org/10.1038/nri2747
doi: 10.1038/nri2747
pubmed: 20414207
Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O’Shaughnessy JA (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy [Clinical Trial, Phase II Multicenter Study]. J Clin Oncol 29(4):398–405. https://doi.org/10.1200/JCO.2010.29.5865
doi: 10.1200/JCO.2010.29.5865
pubmed: 21172893
Burstein HJ (2005) The distinctive nature of HER2-positive breast cancers [Comment]. N Engl J Med 353(16):1652–1654. https://doi.org/10.1056/NEJMp058197
doi: 10.1056/NEJMp058197
pubmed: 16236735
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639–2648. https://doi.org/10.1200/JCO.1999.17.9.2639
doi: 10.1200/JCO.1999.17.9.2639
pubmed: 10561337
de Moura Leite L, Cesca MG, Tavares MC, Santana DM, Saldanha EF, Guimaraes PT, Sa DDS, Simoes MFE, Viana RL, Rocha FG, Loose SK, Silva SF, Pirolli R, Fogassa CAZ, Mattos BRS, Campos FAB, Sanches SM, de Lima VCC, Ponde NF (2021) HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res Treat 190(1):155–163. https://doi.org/10.1007/s10549-021-06365-7
doi: 10.1007/s10549-021-06365-7
pubmed: 34409551
Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer EF, Schmitt WD, Hanusch C, Fasching PA, Lubbe K, Solbach C, Huober J, Loibl S (2021) Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 22(8):1151–1161. https://doi.org/10.1016/S1470-2045(21)00301-6
doi: 10.1016/S1470-2045(21)00301-6
pubmed: 34252375
Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N (2020) NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2 [Clinical Trial, Phase III Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. J Clin Oncol 38(5):444–453. https://doi.org/10.1200/JCO.19.01455
doi: 10.1200/JCO.19.01455
pubmed: 31821109
Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, Schmitt C, Zabernigg AF, Egle D, Sandholzer M, Singer CF, Roitner F, Hager C, Andel J, Hubalek M, Knauer M, Greil R (2021) Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-registry [Research Support, Non-U.S. Gov’t]. Breast Cancer Res 23(1):112. https://doi.org/10.1186/s13058-021-01492-x
doi: 10.1186/s13058-021-01492-x
pubmed: 34906198
pmcid: 8670265
Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4(5):361–370. https://doi.org/10.1038/nrc1360
doi: 10.1038/nrc1360
pubmed: 15122207
Hoefnagel LD, van der Groep P, van de Vijver MJ, Boers JE, Wesseling P, Wesseling J, van der Wall E, van Diest PJ (2013) Discordance in ERalpha, PR and HER2 receptor status across different distant breast cancer metastases within the same patient [Research Support, Non-U.S. Gov’t]. Ann Oncol 24(12):3017–3023. https://doi.org/10.1093/annonc/mdt390
doi: 10.1093/annonc/mdt390
pubmed: 24114857
Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y, Ozaki Y, Sugino K, Kataoka A, Kotani H, Yoshimura A, Hattori M, Sawaki M, Iwata H (2022) The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer 29(2):234–241. https://doi.org/10.1007/s12282-021-01303-3
doi: 10.1007/s12282-021-01303-3
pubmed: 34622383
Hubner J, Katalinic A, Waldmann A, Kraywinkel K (2020) Long-term Incidence and mortality trends for breast cancer in Germany. Geburtshilfe Frauenheilkd 80(6):611–618. https://doi.org/10.1055/a-1160-5569
doi: 10.1055/a-1160-5569
pubmed: 32565551
pmcid: 7299687
Hwang KT, Kim J, Jung J, Chang JH, Chai YJ, Oh SW, Oh S, Kim YA, Park SB, Hwang KR (2019) Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database. Clin Cancer Res 25(6):1970–1979. https://doi.org/10.1158/1078-0432.CCR-18-2782
doi: 10.1158/1078-0432.CCR-18-2782
pubmed: 30559169
Jacot W, Maran-Gonzalez A, Massol O, Sorbs C, Mollevi C, Guiu S, Boissiere-Michot F, Ramos J (2021) Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers. Cancers. https://doi.org/10.3390/cancers13236059
doi: 10.3390/cancers13236059
pubmed: 34885167
pmcid: 8656488
Kirchner M, Kluck K, Brandt R, Volckmar AL, Penzel R, Kazdal D, Endris V, Neumann O, Seker-Cin H, Goldschmid H, Glade J, Allgauer M, Kriegsmann M, Winter H, Muley T, Perner S, Frost N, Reck M, Frohling S, Stenzinger A (2021) The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. ESMO Open 6(5):100253. https://doi.org/10.1016/j.esmoop.2021.100253
doi: 10.1016/j.esmoop.2021.100253
pubmed: 34487971
pmcid: 8426209
Lambein K, Van Bockstal M, Vandemaele L, Geenen S, Rottiers I, Nuyts A, Matthys B, Praet M, Denys H, Libbrecht L (2013) Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. Am J Clin Pathol 140(4):561–566. https://doi.org/10.1309/AJCP4A7KTAYHZSOE
doi: 10.1309/AJCP4A7KTAYHZSOE
pubmed: 24045554
Lee J, Park YH (2022) Trastuzumab deruxtecan for HER2+ advanced breast cancer. Future Oncol 18(1):7–19. https://doi.org/10.2217/fon-2021-0550
doi: 10.2217/fon-2021-0550
pubmed: 34823373
Marchio C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A (2021) Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol 72:123–135. https://doi.org/10.1016/j.semcancer.2020.02.016
doi: 10.1016/j.semcancer.2020.02.016
pubmed: 32112814
Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Conte P, Guarneri V, Dieci MV (2021) Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer 7(1):137. https://doi.org/10.1038/s41523-021-00343-4
doi: 10.1038/s41523-021-00343-4
pubmed: 34642348
pmcid: 8511010
Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S (2020) Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol 38(17):1887–1896. https://doi.org/10.1200/JCO.19.02318
doi: 10.1200/JCO.19.02318
pubmed: 32058843
pmcid: 7280051
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9–20. https://doi.org/10.1056/NEJMoa2203690
doi: 10.1056/NEJMoa2203690
pubmed: 35665782
Onsum MD, Geretti E, Paragas V, Kudla AJ, Moulis SP, Luus L, Wickham TJ, McDonagh CF, MacBeath G, Hendriks BS (2013) Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients [Research Support, Non-U.S. Gov’t]. Am J Pathol 183(5):1446–1460. https://doi.org/10.1016/j.ajpath.2013.07.015
doi: 10.1016/j.ajpath.2013.07.015
pubmed: 24035511
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. Nature 406(6797):747–752. https://doi.org/10.1038/35021093
doi: 10.1038/35021093
pubmed: 10963602
Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 5(7): 953–962. https://www.ncbi.nlm.nih.gov/pubmed/1973830
Rossi V, Sarotto I, Maggiorotto F, Berchialla P, Kubatzki F, Tomasi N, Redana S, Martinello R, Valabrega G, Aglietta M, Ponzone R, Montemurro F (2012) Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. Oncologist 17(11):1418–1425. https://doi.org/10.1634/theoncologist.2012-0194
doi: 10.1634/theoncologist.2012-0194
pubmed: 22951668
pmcid: 3500362
Sapino A, Maletta F, Verdun di Cantogno L, Macri L, Botta C, Gugliotta P, Scalzo MS, Annaratone L, Balmativola D, Pietribiasi F, Bernardi P, Arisio R, Viberti L, Guzzetti S, Orlassino R, Ercolani C, Mottolese M, Viale G, Marchio C (2014) Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method. Oncologist 19(11):1118–1126. https://doi.org/10.1634/theoncologist.2014-0195
doi: 10.1634/theoncologist.2014-0195
pubmed: 25323485
pmcid: 4221371
Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P (2014) A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria [Comparative Study]. Arch Pathol Lab Med 138(2):213–219. https://doi.org/10.5858/arpa.2012-0617-OA
doi: 10.5858/arpa.2012-0617-OA
pubmed: 24164555
Schettini F, Chic N, Braso-Maristany F, Pare L, Pascual T, Conte B, Martinez-Saez O, Adamo B, Vidal M, Barnadas E, Fernandez-Martinez A, Gonzalez-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Prat A (2021) Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 7(1):1. https://doi.org/10.1038/s41523-020-00208-2
doi: 10.1038/s41523-020-00208-2
pubmed: 33397968
pmcid: 7782714
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182. https://doi.org/10.1126/science.3798106
doi: 10.1126/science.3798106
pubmed: 3798106
Szymiczek A, Lone A, Akbari MR (2021) Molecular intrinsic versus clinical subtyping in breast cancer: a comprehensive review [Research Support, Non-U.S. Gov’t Review]. Clin Genet 99(5):613–637. https://doi.org/10.1111/cge.13900
doi: 10.1111/cge.13900
pubmed: 33340095
Tan R, Ong WS, Lee KH, Lim AH, Park S, Park YH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Ryu HS, Han W, Tan VKM, Wong FY, Yap YS (2022) HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. BMC Med 20(1):105. https://doi.org/10.1186/s12916-022-02284-6
doi: 10.1186/s12916-022-02284-6
pubmed: 35296300
pmcid: 8928638
Tarantino P, Gandini S, Nicolo E, Trillo P, Giugliano F, Zagami P, Vivanet G, Bellerba F, Trapani D, Marra A, Esposito A, Criscitiello C, Viale G, Curigliano G (2022) Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer 163:35–43. https://doi.org/10.1016/j.ejca.2021.12.022
doi: 10.1016/j.ejca.2021.12.022
pubmed: 35032815
Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, Dewar JA, Purdie CA (2010) Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the breast recurrence in tissues study (BRITS) [Multicenter Study Research Support, Non-U.S. Gov’t]. Breast Cancer Res 12(6):R92. https://doi.org/10.1186/bcr2771
doi: 10.1186/bcr2771
pubmed: 21059212
pmcid: 3046433
Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN (2015) Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 33(24):2695–2704. https://doi.org/10.1200/JCO.2015.61.1459
doi: 10.1200/JCO.2015.61.1459
pubmed: 26195705
pmcid: 5478102
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791. https://doi.org/10.1056/NEJMoa1209124
doi: 10.1056/NEJMoa1209124
pubmed: 23020162
pmcid: 5125250
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Hayes DF (2007a) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [Guideline]. J Clin Oncol 25(1):118–145. https://doi.org/10.1200/JCO.2006.09.2775
doi: 10.1200/JCO.2006.09.2775
pubmed: 17159189
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, American Society of Clinical Oncology/College of American P (2007b) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18–43. https://doi.org/10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;210.5858/2007-131-18-ASOCCO
doi: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;210.5858/2007-131-18-ASOCCO
pubmed: 19548375
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, College of American P (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. https://doi.org/10.1200/JCO.2013.50.9984
doi: 10.1200/JCO.2013.50.9984
pubmed: 24101045
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, College of American P (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138(2):241–256. https://doi.org/10.5858/arpa.2013-0953-SA
doi: 10.5858/arpa.2013-0953-SA
pubmed: 24099077
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36(20):2105–2122. https://doi.org/10.1200/JCO.2018.77.8738
doi: 10.1200/JCO.2018.77.8738
pubmed: 29846122
Won HS, Ahn J, Kim Y, Kim JS, Song JY, Kim HK, Lee J, Park HK, Kim YS (2022) Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Res 24(1):22. https://doi.org/10.1186/s13058-022-01519-x
doi: 10.1186/s13058-022-01519-x
pubmed: 35307014
pmcid: 8935777
Wynn CS, Tang SC (2022) Anti-HER2 therapy in metastatic breast cancer: many choices and future directions [Review]. Cancer Metastasis Rev. https://doi.org/10.1007/s10555-022-10021-x
doi: 10.1007/s10555-022-10021-x
pubmed: 35142964
pmcid: 8924093